Ascletis Pharma Inc. announces that ASC40, a first-in-class, once-daily oral fatty acid synthase inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acne vulgaris.
Ascletis Pharma Inc. announces that ASC40, a first-in-class, once-daily oral fatty acid synthase inhibitor, achieved primary and key secondary endpoints in Phase II clinical trial for acne vulgaris.